Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

Y0001183

Trolamine impurity B

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Diethanolamine, 2,2′-Iminodiethanol, Bis(2-hydroxyethyl)amine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula condensata:
HN(CH2CH2OH)2
Numero CAS:
111-42-2
Peso molecolare:
105.14
Beilstein:
605315
Numero MDL:
MFCD00002843
Codice UNSPSC:
41116107
ID PubChem:
329831296
NACRES:
NA.24

Grado

pharmaceutical primary standard

Densità del vapore

3.6 (vs air)

Tensione di vapore

<0.98 atm ( 100 °C)

Famiglia di API

trolamine

Temp. autoaccensione

689 °F

Limite di esplosione

10.6 %

Produttore/marchio commerciale

EDQM

Indice di rifrazione

n20/D 1.477 (lit.)

P. eboll.

217 °C/150 mmHg (lit.)

Punto di fusione

28 °C (lit.)

Densità

1.097 g/mL at 25 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

OCCNCCO

InChI

1S/C4H11NO2/c6-3-1-5-2-4-7/h5-7H,1-4H2
ZBCBWPMODOFKDW-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Trolamine impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Avvertenze

Danger

Indicazioni di pericolo

H302,H315,H318,H361fd,H373

Classi di pericolo

Acute Tox. 4 Oral - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - STOT RE 2 Oral

Organi bersaglio

Kidney,Liver,Blood

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

280.4 °F - closed cup

Punto d’infiammabilità (°C)

138 °C - closed cup

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Choline deficiency associated with diethanolamine carcinogenicity.
Paul M Newberne
Toxicological sciences : an official journal of the Society of Toxicology, 67(1), 1-3 (2002-04-19)
Hon-Wing Leung et al.
Regulatory toxicology and pharmacology : RTP, 43(3), 260-271 (2005-09-29)
Diethanolamine (DEA) is a chemical used widely in a number of industries and is present in many consumer products. Studies by the National Toxicology Program (NTP) have indicated that lifetime dermal exposure to DEA increased the incidence and multiplicity of
M-L Metzger et al.
Clinical and experimental immunology, 179(2), 256-264 (2014-09-25)
Common variable immunodeficiency (CVID) encompasses a heterogeneous group of antibody deficiencies characterized by susceptibility to recurrent infections and sequelae, including bronchiectasis. We investigated the relevance of the lectin complement pathway in CVID patients by analysing ficolin-2 and ficolin-3 serum levels
Hae-Rim Kim et al.
PloS one, 10(4), e0124909-e0124909 (2015-04-22)
Vascular endothelial growth factor (VEGF) has angiogenic, inflammatory, and bone-destructive roles in rheumatoid arthritis (RA). We aimed to determine the unique role of VEGF in osteoclastogenesis in RA. VEGF-induced receptor activator of nuclear factor ҡB ligand (RANKL) expression was determined
Domtila Kimani et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 22(11), 1992-2003 (2014-06-17)
To induce a deployable level of efficacy, a successful malaria vaccine would likely benefit from both potent cellular and humoral immunity. These requirements are met by a heterologous prime-boost immunization strategy employing a chimpanzee adenovirus vector followed by modified vaccinia
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.